Holen Sie sich die Stockscreener-App
17.76
1.99%
-0.36
Schlusskurs vom Vortag:
$18.12
Offen:
$18.04
24-Stunden-Volumen:
790.65K
Relative Volume:
0.79
Marktkapitalisierung:
$1.50B
Einnahmen:
$42.95M
Nettoeinkommen (Verlust:
$-130.01M
KGV:
-10.91
EPS:
-1.6278
Netto-Cashflow:
$-19.66M
1W Leistung:
+6.92%
1M Leistung:
-2.15%
6M Leistung:
-4.82%
1J Leistung:
+268.46%
1-Tages-Spanne:
$17.38
$18.50
1-Wochen-Bereich:
$16.28
$19.00
52-Wochen-Spanne:
$4.12
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
17.76 | 1.53B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by Alphabet Inc. - MarketBeat
Director at Monte Rosa (GLUE) awarded 25,800 stock options - Stock Titan
Monte Rosa Therapeutics (GLUE) director receives 25,800 stock options grant - Stock Titan
Monte Rosa Therapeutics (GLUE) director gets 25,800 options grant - Stock Titan
Monte Rosa Therapeutics (GLUE) grants director Jan Skvarka 25,800 options - Stock Titan
Monte Rosa Therapeutics (GLUE) director awarded 25,800 stock options - Stock Titan
Monte Rosa Therapeutics (GLUE) director granted 25,800 stock options - Stock Titan
Director at Monte Rosa (NASDAQ: GLUE) awarded 25,800 stock options - Stock Titan
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential - Seeking Alpha
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics (NASDAQ: GLUE) shareholders elect directors, ratify auditor - Stock Titan
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? - Investing.com
GLUE Technical Analysis & Stock Price Forecast - Intellectia AI
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy - Insider Monkey
We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate - Moomoo
10 Best Growth Stocks Under $20 to Buy - Insider Monkey
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan - Stock Titan
Monte Rosa Therapeutics (GLUE) amends Form 144; RSU award and sales noted - Stock Titan
Monte Rosa (GLUE) insider Markus Warmuth reports multiple sales on Form 144 - Stock Titan
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
Monte Rosa COO Jennifer Champoux sells $43,500 in stock By Investing.com - Investing.com Nigeria
Monte Rosa COO Jennifer Champoux sells $43,500 in stock - Investing.com India
Monte Rosa Therapeutics (NASDAQ: GLUE) COO exercises options and sells 2,175 shares - Stock Titan
GLUE (NASDAQ: GLUE) Form 144: proposed sale of 2,175 shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) COO exercises options and sells 2,176 shares under plan - Stock Titan
Monte Rosa Therapeutics director sells $180,100 of Glue shares By Investing.com - Investing.com India
Monte Rosa Therapeutics director sells $180,100 of Glue shares - Investing.com UK
Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares - Stock Titan
IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development - Traders Union
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Monte Rosa lines up TD Cowen and Jefferies investor talks - Stock Titan
Vanguard Group Inc. Has $50.91 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Monte Rosa Therapeutics (GLUE) — TCG/Chen Yu report 5.5% holding - Stock Titan
[SCHEDULE 13G/A] Monte Rosa Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
BVF Group (GLUE) entities report up to 5.09M shares, 6.3% total - Stock Titan
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
EX-99.1 - SEC.gov
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar - Traders Union
Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention - Yahoo Finance
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):